

October 2020

## CURRICULUM VITAE

### PERSONAL INFORMATION

**NAME:** Steven B. Deitelzweig, MD, MMM, SFHM. FACP, FACC  
Professor of Medicine - University of Queensland,  
Ochsner Clinical School

**BUSINESS ADDRESS:** Ochsner Clinic Foundation, Hospital Medicine  
And Business Development  
Eleventh Floor, Hospital Medicine  
1514 Jefferson Highway, New Orleans, Louisiana 70121  
Phone (504) 842-5766  
Pager 1-877-419-6271  
Cell (504) 296-8204  
Fax (504) 842-6617  
Internet: sdeitelzweig@ochsner.org

**HOME ADDRESSES:** 1610 Bordeaux Street, New Orleans, Louisiana 70115  
11606 Privado Way, Boynton Beach, Florida 33437

**DATE/PLACE OF BIRTH:** December 6, 1963 -- New York

**MARITAL STATUS:** Married: Stacy Dobbins Deitelzweig  
Children: Chelsea Tate and Chloe Cate

### EDUCATION AND TRAINING

**EDUCATION:** B.A. Degree, Summa Cum Laude  
Vassar College  
1981 - 1985

M.D. Degree  
State University of New York  
at Stony Brook School of Medicine  
1985 - 1989

**RESIDENCY:** Cornell University Medical College  
North Shore University Hospital  
Resident in Internal Medicine (R1-R3)  
1989-1992

**FELLOWSHIP:** Department of Internal Medicine  
Alton Ochsner Medical Foundation  
New Orleans, Louisiana  
Fellowship in Hepatology  
1992 - 1993

University of New Orleans / Ochsner Clinic  
Executive College for Health Care Professionals  
1996 - 1997

University of New Orleans / Ochsner Clinic  
Advanced Executive College for Health Care Professionals  
1998 - 1999  
Ochsner Clinic Foundation  
New Orleans, Louisiana  
Specialized Training in Vascular Medicine  
2001-2002

Master of Medical Management (MMM)  
Tulane University School of Public Health and Tropical  
Medicine  
2006- 2008

Academy GE Fellows Program for Physician Executives  
Fall 08 class – 8 candidates. Completed April, 2011

## **PROFESSIONAL DATA**

### **CERTIFICATION:**

American Board of Internal Medicine, 1992, 2002, 2012 with  
Focused Practice in Hospital Medicine  
Certified Medical Director 1997  
American Board of Hospice and Palliative Medicine 2000  
Registered Vascular Technologist 2002

### **LICENSURE:**

State of Louisiana, #0921R, 1992  
State of Florida, #ME 96968, 2006  
State of New York, #185678, 1991 - inactive

**PRESENT POSITION: Medical Director of Regional  
Business Development and System Chairman, Department  
of Hospital Medicine**

**IMMEDIATE PRIOR POSITION: Regional Vice  
President of Medical Affairs, Ochsner Medical Center and  
System Department Chairman of Hospital Medicine,  
Ochsner Health System, New Orleans, Louisiana.**

The Ochsner Clinic Foundation is a 501(c) 3 tax exempt independent Academic Medical Center in the Greater New Orleans and Baton Rouge areas. The provider component with net revenues of \$3.5 billion, includes a 1300 physician multi-specialty, multi-site physician group; nine acute care hospitals and one sub-acute rehabilitation. This position reports to the System Chief Medical Officer. This includes overseeing medical affairs, quality, clinical resource management, patient satisfaction, case management staff and clinical performance improvement functions. Current initiatives include goals to achieve zero unexpected, preventable deaths and zero post-op class 1 surgical infections.

90 physicians, 35 NPs and PAs in New Orleans, Kenner  
Westbank, Baton Rouge, Shreveport and Northshore Louisiana.  
Hancock, Mississippi  
Assistant Program Director for Internal Medicine  
Staff Physician, Section of Vascular Medicine  
Ochsner Heart and Vascular Institute  
Ochsner Clinic Foundation  
New Orleans, Louisiana  
July 1993 – 2007  
NBC News Medical Correspondent.  
WDSU weekly medical segment titled: “Ask Dr. D”.  
2007-2012

Physician mentor for Tulane University Medical College  
MD/MPH program.  
2008 - present

Total Quality Management Course  
Course Director  
Tulane University – Health System Management  
Adjunct Professor  
2008 - present

**APPOINTMENTS:**

Medical Leadership Council Member  
Ochsner Clinic  
3/99 – 1/13

CEOs Physician Strategy Cabinet  
Ochsner Health System  
1/13 - present

Staff Executive Committee  
Ochsner Foundation Hospital  
Member 1997 – 2001  
Secretary 2002 – 12/2003  
Vice President 1/2004 – 12/31/05  
President – 1/06 – 12/07  
Member – ex officio – 1/08 to present

Credentials Committee  
Ochsner Health System  
Member 1997 – 2005, 3/07 - present  
Chairman 1/2006 – 3/07  
Member – ex officio – 1/08 to present

Practice Management Committee  
Society of Hospital Medicine  
Chairman – 2009 – 2013  
Member – 2014 to 2015

Multi-Site Leaders Task Force

Member – 2014 - 2016

Society of Hospital Medicine Key Characteristic Work Group  
Chairman  
2015 - present

Society of Hospital Medicine  
Board of Directors  
2017 - present

AMA (American Medical Association)  
House of Delegates Representative  
Society of Hospital Medicine  
2016 - present

Gulf States Hospital Society  
Leadership including Presidency 1/2007 – present

Society of Cardiovascular Patient Care  
Board of Directors – member  
2011 – 2016

American College of Cardiology  
Accreditation Management Board  
Board of Directors  
2016 - present

Anticoagulation (AC) Forum  
Board of Directors – elected member  
April 2017 – present  
Current 3 year term

Leadership Task Force  
Society of Hospital Medicine  
2004 – 2005

Annual Meeting Committee  
Society of Hospital Medicine  
Member 2005 – 2006, 2006 – 2007, 2007-2008, 2009 - 2010

Core Curriculum Committee  
Society of Hospital Medicine  
Member 2006 – 2007  
Benchmarks, Practice Analysis Committee  
Society of Hospital Medicine  
Member 2006 – 2007, 2007 – 2008, 2008 – 2009

CME Executive Committee  
Member  
Ochsner Health System  
2006 - present

System Throughput Steering Committee Member

2007 - 2013

LEARN (Louisiana Education on Anticoagulation  
Resource Network) Physician Advisor  
1/02 – 2012

System Quality Care Committee  
Steering Committee Member  
Ochsner Health System / Ardent  
2006 - 2008

Anticoagulation Subcommittee, System Chairman  
9/01 – present

Professor of Medicine  
Ochsner Clinical School with University of Queensland  
2019 to present

Associate Professor of Medicine  
Ochsner Clinical School with University of Queensland  
2012 - 2019

Clinical Associate Professor of Medicine  
Tulane University Medical College  
New Orleans, LA; 2001 – present

Clinical Associate, Department of Medicine  
Cornell University Medical College  
New York, NY; 1989 - 1992

Medical Director of Jefferson Healthcare Nursing Home  
New Orleans, LA; 1992 – 4/02

Co-Director, Nutrition Support Team  
New Orleans, LA; 1993 - 2007

Utilization Management Medicare Risk Committee  
Ochsner Foundation Hospital; New Orleans, LA  
Member 1/96 - 12/96  
Chairman 1/97 - 12/99  
Medical Director 1/00 – 12/09

Hospice Associates of America  
Medical Director 1997 - 7/98  
Associate Director 8/98 - 7/99

Hospice of Greater New Orleans  
Medical Director 7/99 - Present  
National Consultant 1/00 – 1/02

Medicare Risk Physician Liaison  
Ochsner Foundation Hospital  
1996 -2009

Board of Directors, Ochsner Home Health  
1996 – 2009

Patient Care Education Committee Member  
Ochsner Clinic  
1997 - present

Urgent Care Committee Member  
Ochsner Clinic  
1996 - 1/99

Information Systems Steering Committee Member  
Epic implementation planned for 2011  
Ochsner Foundation Hospital  
1997 – present

**PROFESSIONAL  
AFFILIATIONS:**

Society of Hospital Medicine  
American College of Physicians  
American College of Cardiology  
American College of Physician Executives  
Society of Cardiovascular Patient Care  
Alliance of Independent Academic Medical Centers  
American Medical Association  
Anticoagulation Forum  
Society for Vascular Medicine and Biology  
Investigators Against Thromboembolism  
North American Thrombosis Foundation  
International Society of Thrombosis and Hemostasis  
American Medical Director Association  
Medical Society of the State of New York  
Southern Medical Association  
Louisiana State Medical Society  
National Hospice Organization

**HONORS AND  
AWARDS:**

Delta Omega National Honor Society  
in Public Health (Eta Chapter)  
Inducted 5/08 - National guidelines state that each chapter can  
induct 10% of their graduating class who should be  
selected from the top 25% when ranked by GPA.

2018-2019 FDA contract to develop the Core Elements of an  
Anticoagulation Stewardship program  
Chairman of the Administrative Oversight Gap Report to  
identify opportunities for advancing anticoagulation  
stewardship through optimal alignment of government  
regulations, incentive programs, accreditation standards, and  
quality measures

Stroke Journal Second Place Stroke Progress and Innovation

Award Winner for ARISTOPHANES presented at ISC Feb 2020

Outstanding student for the MMM Class of 2008  
Tulane University Health Science Center  
Health System Management – 3.95 GPA

System Department of the Year  
Business Development 2016 and 2017 – One of Three Finalists  
Hospital Medicine 2009  
Ochsner Health System

Physician Leader of the Year  
Ochsner Health System 2007

Physician of the Year – One of Three Finalists for 2005  
Ochsner Health System

Cover Story of American College of Physicians Hospitalist –  
Practice Management during COVID-19

Editorial Board - Hospitalist News

Editorial Board – OmniaCore in Hospital Medicine

Editorial Board – Society of Cardiovascular Patient Care

Reviewer – Journal of Hospital Medicine, Thrombosis and Hemostasis

Reviewer – CHEST since 1/07, Thrombosis and Hemostasis, ACP Hospitalist, Hospitalist News, American Journal of Cardiovascular Drugs, and Hospital Practice

Editorial Advisory Board – Hospitalist and Inpatient Management Report 2006 - 2007

Emergency Medicine - Editorial Board – 2005

Reviewer – Vascular Surgery since 1/07

Top Doctors – 2006-2018  
New Orleans Magazine

Top Doctors 2007 - present  
Louisiana Life Magazine

Best Doctors in America 2005 - 2018  
(Guide to America's Top Physicians)

Quantia MD– prior Director

GME – Today Reviewer and Author – 2004, 2005, 2006

Fellow of the Society for Vascular Medicine and Biology –  
7/02 – present

Chair, Department of Medicine Chair Search Committee 1999

Hospitalist Programs; Medical Leadership Council for the  
Advisory Board Company; Advisor – 1998

Fellow of the American College of Physicians; 7/98 – present  
Honorable Mention, Ochsner Clinic Department of Medicine  
Teacher of the Year - 1994, 1995, 1996, 1997,  
1998, 1999, 2000, 2001

George M. Jaffin Scholarly Activity Award for Excellence  
in Research - 1991

Assistant Chief Medical Resident - 1991

Certificate of Achievement in Hospice Training - 1989

Distinctions for Independent Research on Medicine in China  
and China Today - 1985

### **RESEARCH and ABSTRACTS**

1. Medicine in China: Acupuncture (100-page thesis), 1985
2. Deitelzweig S, Foley C, Wolf-Klein GP: The Effects of Hyperglycemia on Alzheimer's Disease. Nerken Center for Geriatric Research, 1988
3. Deitelzweig S, Grossman D, Klein I, Gottridge J: Hypercholesterolemia as a Marker for Thyroid Disease in an Outpatient Population, 1991
4. Deitelzweig S, Regenstein F: Diagnosis of Metastatic Carcinoma by Transjugular Liver Biopsy, 1993, unpublished
5. Messerli F., Deitelzweig S, sub-investigator: Clinical Trials in Hyponatremia. VPA-985 with Wyeth-Ayerst 1997-1999
6. Messerli F, Deitelzweig S, sub-investigator: RAFT (Rythmol-SR Atrial Fibrillation Trial). Knoll Pharmaceutical 1998
7. Deitelzweig S, Simonson: Pharmacoeconomic Analysis of Outpatient Deep Vein Thromboses 1/2000
8. Messerli F, Deitelzweig S, sub-investigator: A randomized, double-blind, placebo-controlled, multicenter, long-term trial of preventing hypertension using Candesartan Cilexetil 16 mg in patients with high normal blood pressure (TROPHY).



Astra-Zeneca 1999-2000

9. Messerli F, Deitelzweig S, sub-investigator: A randomized, multicenter, double-blind, parallel group study to determine the safety and efficacy of Lotrel versus enalapril in the treatment of hypertension in Type II diabetics. Novartis 1/00
10. Walker C, Deitelzweig S, co-investigator: Economic Analysis of Telemedicine at Home for COPD Patients. Board of Regents Proposal 1/00
11. Deitelzweig S, Money S, co-investigator: Thrive V. A double-blind, efficacy and safety study of the oral direct thrombin inhibitors, H376/95 versus enoxaparin and Coumadin in patients with acute, symptomatic deep venous thrombosis with or without pulmonary embolism. June 2000
12. Deitelzweig S, principal investigator. LITE trial (long-term Innohep Treatment Evaluation). June 2000
13. Messerli F, Deitelzweig S, sub-investigator. A double-blind, randomized, placebo-controlled, parallel group, multicenter, flexible-dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in males with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatment. January 2000
14. Messerli F, Deitelzweig S, sub-investigator. Omapatrilat in Persons with Enhanced Risk of Atherosclerotic Events: The OPERA Trial. May 2001
15. Deitelzweig S, principal investigator. A phase II, multicenter, randomized, open-label prospective study to evaluate Tinzaparin versus unfractionated heparin in subjects who are receiving long-term warfarin and require parenteral anticoagulation after the discontinuation of warfarin therapy for an invasive or surgical procedure. March 2001
16. Deitelzweig S, principal investigator. A pilot feasibility study to evaluate patient recruitment, safety, efficacy, and compliance for a 180-day period of enoxaparin alone versus enoxaparin followed by warfarin in the secondary prevention of venous of venous thromboembolism in patients with active malignancy. July 2001
17. Messerli F, Deitelzweig S. A randomize, placebo-controlled, multicenter, fixed-dose study to compare the blood pressure response of patients with moderate hypertension receiving Lercanidipine 10 mg, 20 mg, 40 mg or placebo. July 2001
18. Deitelzweig S, Simonson D. A bridging trial utilizing enoxaparin for patients with arrhythmias, venous thromboembolic disease and mechanical heart valves. January 2001
19. Deitelzweig S, principal investigator. An Epidemiological Observation Study of Deep Vein Thrombosis DVT Free 10/01 – 4/02
20. Deitelzweig S, principal investigator. Phase III oral heparin/SNAC solution tolerability study. February 2002 – January 2003

21. Deitelzweig S, principal investigator. A Phase IV double-blind, placebo-controlled, parallel, multicenter study on extended VTE prophylaxis in acutely ill medical patients with prolonged immobilization. February 2002 – ongoing
22. Felberg R, Deitelzweig S. WASID study, a 5-year multicenter clinical trial. Coordinating Center: Emory University. Funded by: National Institute of Neurological Disorders and Stroke. February 2002 – 2004
23. Deitelzweig S, principal investigator. A bridging registry with LMWH (Enoxaparin). Started July 2002
24. Simonson D, Deitelzweig S. Safety collaboration for the outpatient environment. Initiation October 2002
25. Deitelzweig S, Alonzo M. Optimize heart failure: Organized program to initiate life-saving treatment in hospitalized patients with heart failure. July 2003
26. Deitelzweig S. EXULT Knee: Optimization of dose and confirmation of safety and efficacy of H376/95 (oral direct thrombin inhibitor compared to warfarin (Coumadin) for the prevention of venous thromboembolism following total knee arthroplasty (TKA). August 2002 – February 2003
27. Deitelzweig S. Enoxaparin for acute ischemic stroke for VTE prophylaxis. PREVAIL. Sponsored by Sanofi-Aventis. December 2003 to December 2005
28. Deitelzweig S. Clinical outcomes with the use of the low molecular weight heparin as perioperative and periprocedural bridging therapy in patients on long-term oral anticoagulant treatment requiring interruption for an elective procedure (REGIMEN) sponsored by Aventis. April 2002 to October 2004
29. Goldman C, Deitelzweig S. A phase II double-blind randomized placebo-controlled study to assess the safety and efficacy of AMG0001 to improve perfusion in critical leg ischemia sponsored by AGNES. January 2003 to 2005
30. Goldman C, Deitelzweig S. A phase II double-blind placebo-controlled parallel group efficacy and safety study of different doses and schedules of administration of NVIFGF in patients with severe peripheral artery occlusive disease. June 2003 to 2006
31. Deitelzweig, S. A multicenter, randomized, open label, prospective comparison of xi Melagatran (Exanta) to low molecular weight heparin (LMWH) or bridging during invasive procedures in patients receiving chronic anticoagulation with vitamin K antagonists (VEA) Evaluation of xi Melagatran in changing anticoagulation in a global environment (EXCHANGE). Sponsored by Astra-Zeneca. April 2004
32. Deitelzweig, S. Improve registry (International medical prevention registry on venous thromboembolism). Sponsored by Center for Outcome Research. June 2004 to 2006
33. Money S, Sternbergh C, Deitelzweig S. Claudication trial with a primary end lovastatin/Niaspan versus placebo for six months, then all patients cross over to lovastatin with continued randomization between niacin and placebo. January 2004 to January 2005

34. Deitelzweig S, Lin J. Comparison of the 2-year clinical and economic outcomes of VTE prophylaxis options in medical patients at risk of VTE. December 2006 to June 2007
35. Deitelzweig S. Multinational multicenter randomized double-blind double-dummy comparison of once daily orally administered rivaroxaban with enoxaparin for the prevention of venous thromboembolism events in acute ill medical patient. Sponsored by Bayer. November 2007 to 2008
36. HIT Observation Thromboembolism study National Health, Lung and Blood Institute Collaboraton with Tulane University Medical Center. June 2008 initiation.
37. Deitelzweig S, Multicenter randomized parallel group efficacy superiority study in hospitalized medically ill patient; comparing rivaroxaban with enoxaparin. Sponsored by Sanofi-Aventis. May 2008 initiation.
38. CASSIOPEA – An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep vein thrombosis.
39. AHRQ sponsored COPD Outcomes-based Network for Clinical Effectiveness and Research Translation: Transitions in Care Working Group. March 2010 – 2012.
40. Deitelzweig S., Lin J., et al. Preventing Venous Thromboembolism Following Hip Replacement Surgery: Analysis of Special Populations in the US who may Require Alteration to Anticoagulant Regimens. Abstract: Journal of Hospital Medicine. April 2010.
41. Deitelzweig S., Lin J., et al. Impact of Special Populations on Thromboprophylaxis and Clinical Outcomes of Patients undergoing Knee Replacement Surgery in the U.S. Abstract: Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference. Washington, D.C. May 2010
42. Impact of CMS VTE Hospital Acquired Conditions (HAC) Policy on Hospital Cost and Revenue Associated with Major Surgical Hip and Knee Procedures. American Society of Hematology. Orlando, Florida. December 2010.
43. Medical Cost Avoidance among the General and Elderly Atrial Fibrillation Populations Differs According to Specific Anticoagulant Use, Based on the ARISTOTLE and RE-LY Trials. American Heart Association: QoC. Atlanta, Georgia. May 2012.
44. Evaluation of Total Medical Costs with the Use of Apixaban and Rivaroxaban vs. Warfarin Among Atrial Fibrillation Patients. American Heart Association: QoC. Atlanta, Georgia. May 2012.
45. Predicting total medical cost reductions of NOACs vs. warfarin from the RE-LY, ROCKET-AF and ARISTOTLE trials with adjustment for warfarin's time in therapeutic n Society of Health System Pharmacists. Baltimore, Maryland. June 2012.

46. Impact of warfarin's time in therapeutic range on the efficacy and safety of stroke prevention among non-valvular atrial fibrillation patients. American Society of Health System Pharmacists. Baltimore, Maryland. June 2012.
47. Predicting Impact of Warfarin's Time-in-Therapeutic Range on Stroke and Major Bleed Rates and its Influence on Medical Cost Avoidance Associated with NOAC usage— Learning from RE-LY, ROCKET-AF and ARISTOTLE Trials. Thrombosis and Hemostasis Society of North America. Chicago, Illinois. May 2012.
48. Costs of Patients with Nonvalvular Atrial Fibrillation Who have Bleeding Events in a Large Managed Care Population. American College of Cardiology. San Francisco, California. March 2013.
49. Evaluation of Medical Costs Associated with Use of Novel Oral Anticoagulants Compared with Warfarin Among Nonvalvular Atrial Fibrillation Patients with Moderate and High Stroke Risk. American Heart Association: QCOR. Baltimore, MD May 2013
50. Evaluation of differences in medical costs associated with venous thromboembolism prophylaxis with desirudin vs. low molecular weight heparin among patients undergoing total hip replacement surgery. American Society of Hematology 56<sup>th</sup> Annual Meeting, San Francisco, CA, December 6-9, 2014. Poster.
51. An In-Hospital Discharge Protocol for Optimal Care of Patients with Chronic Obstructive Pulmonary Disease. Society of Hospital Medicine. Washington DC May 2015
52. A conservative approach to assess warfarin time-in-therapeutic ranges among nonvalvular atrial fibrillation patients in an integrated healthcare delivery setting in the U.S. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting, Philadelphia, PA, May 16-20, 2015, Poster
53. Real-world assessment of hospital readmission among hospitalized patients with nonvalvular atrial fibrillation treated with new oral anticoagulants – An early evaluation. Academy of Managed Care Pharmacy 27th Annual Meeting and Expo, San Diego, CA, April 7-10, 2015. Poster.
54. Quality of warfarin therapy and its impact on healthcare resource utilization and costs among nonvalvular atrial fibrillation patients in an integrated delivery network setting in the U.S. Society of Hospital Medicine Annual Meeting, National Harbor, MD, March 29-April 1, 2015. Poster.
55. Does warfarin time-in-therapeutic range affect healthcare resource utilization and costs among nonvalvular atrial fibrillation patients in the U.S.? American College of Cardiology 64<sup>th</sup> Annual Scientific Sessions and Expo, San Diego, CA, March 14-16, 2015. Poster.
56. Comparison of All-cause and Bleeding-related Hospitalizations among Non-Valvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. 2015 AHA.
57. Hospitalization Rates and Healthcare Costs Among Non-Valvular Atrial Fibrillation Patients who were Naïve Users of Oral Anticoagulants. Quality of Care and Outcomes Research (QCOR), April 29-May 1, 2015. Baltimore, MD.

58. Impact of warfarin adherence status on healthcare costs among patients with nonvalvular atrial fibrillation. 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA, April 19-22, 2016. Poster.
59. Hospital readmissions among patients with nonvalvular atrial fibrillation treated with the new oral anticoagulants, apixaban, dabigatran, and rivaroxaban. American College of Cardiology 65th Scientific Sessions, Chicago, IL, April 2-4, 2016. Poster.
60. Healthcare Costs among Patients Diagnosed with Deep Vein Thrombosis in the Outpatient Setting and Treated with Rivaroxaban versus Low-Molecular-Weight Heparin and Warfarin. Poster presentation at the International Society for Pharmacoeconomics & Outcomes Research (ISPOR) International meeting. May 21-24, 2016. Washington, DC.
61. Hospital Length of Stay and Hospitalization Costs for Pulmonary Embolism Comparing Patients Receiving Rivaroxaban or Warfarin. Poster presentation at the 2016 American Thoracic Society (ATS). May 13-18, 2016. San Francisco, California.
62. Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting (ESC). August 27 – 31, 2016. Rome, Italy.
63. Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitors (ESC). August 27 – 31, 2016. Rome, Italy.
64. Incremental Economic Burden Associated with Major Bleeding among Atrial Fibrillation Patients Treated with Factor Xa Inhibitors (ACEP). October 16 – 19, 2016. Las Vegas, Nevada.
65. Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin. Moderated poster presentation. American College of Cardiology (ACC). March 17, 2017. Washington DC, Maryland.
66. Impact of Direct Oral Anticoagulants on Major Bleeding Rates in Patients With Non-Valvular Atrial Fibrillation: Evidence From Real-World Studies. American College of Cardiology's 66th Annual Scientific Session. March 17, 2017. Washington DC, Maryland.
67. Effectiveness and Safety of Apixaban Compared to Warfarin in Non-Valvular Atrial Fibrillation: Patients in “Real-World” US Clinical Practice: An Analysis of Three Large Databases. AHA QCOR. 4/2/2017. Arlington, Virginia.
68. Comparison of Major Bleeding Risk Among Elderly Nonvalvular Atrial Fibrillation Patients Treated with Apixaban vs. Rivaroxaban and Dabigatran. 14<sup>th</sup> Anticoagulation Forum National Conference. April 20, 2017. Los Angeles, California.
69. Effectiveness and Safety of Apixaban versus Warfarin among High-Risk Subgroups of

- Nonvalvular Atrial Fibrillation Patients: a Propensity Score Matched Analysis, *European Heart Journal*, 38 (suppl\_1):P3588, European Society of Cardiology August, 2017 annual meeting abstract (poster presentation). Barcelona, Spain.
70. Effectiveness and Safety of Standard and Lower Dose Apixaban Compared to Warfarin in Nonvalvular Atrial Fibrillation Patients: a Propensity Score Matched Analysis, *European Heart Journal*, 38 (suppl\_1):P3603, European Society of Cardiology August, 2017 annual meeting abstract (poster presentation). Barcelona, Spain.
  71. Real-World Comparison of Major Bleeding Risk Associated with Direct Oral Anticoagulants or Warfarin in Patients with Non-Valvular Atrial Fibrillation: a Systematic Review and Network Meta-Analysis, *European Heart Journal*, 38 (suppl\_1):P2691, European Society of Cardiology August, 2017 annual meeting abstract (poster presentation) Barcelona, Spain.
  72. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban among Non-Valvular Atrial Fibrillation Patients: a Propensity Score Matched Analysis of Four Large Databases, *Circulation*, 136(Suppl 1):A16462, American Heart Association November, 2017 annual meeting abstract (poster presentation). Anaheim, California.
  73. Effectiveness and Safety of Apixaban Compared to Other Oral Anticoagulants among Non-Valvular Atrial Fibrillation Patients with Coronary Artery Disease or Peripheral Arterial Disease: a Propensity Score Matched Analysis of Four Large Databases,” *Circulation*, 136(Suppl 1):A15998, American Heart Association November, 2017 annual meeting abstract (poster presentation). Anaheim, California.
  74. Comparison of Effectiveness, Safety, and the Net Clinical Outcome Between Different Direct Oral Anticoagulants in 162,707 Non-Valvular Atrial Fibrillation Patients Treated in US Clinical Practice. American College of Cardiology. Orlando, Florida. March 2018.
  75. Comparisons of Clinical and Economic Outcomes between Non-VKA Oral Anticoagulants among Non-valvular Atrial Fibrillation Patients: The ARISTOPHANES Study. European Society of Cardiology annual symposium August 2018 (poster presentation). Munich, Germany.
  76. Comparative Effectiveness and Safety between Non-VKA Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients: A Dose Subgroup Analysis of the ARISTOPHANES Study. European Society of Cardiology annual symposium August 2018 (poster presentation). Munich, Germany.
  77. Comparative effectiveness and safety of non-vitamin K agonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study. European Society of Cardiology annual symposium August 2018 (poster presentation). Munich, Germany.

**CURRICULUM VITAE**

**STEVEN B. DEITELZWEIG, M.D.**

**PAGE 15**

78. Comparisons of Clinical and Economic Outcomes between non-VKA Oral Anticoagulants and Warfarin among Non-valvular Atrial Fibrillation Patients: The ARISTOPHANES Study. European Society of Cardiology annual symposium August 2018 (poster presentation). Munich, Germany.
79. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants among Very Elderly Patients with Non-Valvular Atrial Fibrillation: An Observational Study (Oral Presentation). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
80. Non-Vitamin K Antagonist Oral Anticoagulants Associated with Lower Stroke Rates Compared to Warfarin among Very Elderly Patients with Non-valvular Atrial Fibrillation: An ARISTOPHANES Subgroup Analysis (Moderated Digital Poster). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
81. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants among Patients with Non-Valvular Atrial Fibrillation and Diabetes (Poster). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
82. Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin among Patients with Non-Valvular Atrial Fibrillation and Diabetes: ARISTOPHANES Diabetes Subgroup Analysis (Poster). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
83. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin Among Frail Patients with Non-Valvular Atrial Fibrillation: An Observational Study (Oral Presentation). American College of Cardiology annual symposium (poster presentation). New Orleans, Louisiana. March 2019
84. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin Among Obese Patients with Non-Valvular Atrial Fibrillation: An Observational Study (Oral Presentation). American College of Cardiology annual symposium (poster presentation). New Orleans, Louisiana. March 2019
85. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus NOAC Among Obese Patients with Non-Valvular Atrial Fibrillation: An Observational Study (Oral Presentation). American College of Cardiology annual symposium (poster presentation). New Orleans, Louisiana. March 2019
86. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus NOAC Among Frail Patients with Non-Valvular Atrial Fibrillation: An Observational Study (Oral Presentation). American College of Cardiology annual symposium (oral moderated poster presentation). New Orleans, Louisiana. March 2019
87. Comparison of Major Bleeding- and Stroke-related Hospital Readmissions Among

- Hospitalized Nonvalvular Atrial Fibrillation Patients Treated with Warfarin and Apixaban in the US. American College of Cardiology annual symposium March 2019 (poster presentation). New Orleans, Louisiana.
88. Effectiveness and Safety of Apixaban, Dabigatran and Rivaroxaban versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation: ARISTOPHANES Subgroup Analysis. Cardiometabolic Health Congress October, 2019 (poster presentation). Chicago, Illinois.
89. Comparison of Inpatient Admission Rates of Patients Treated with Apixaban vs. Warfarin for Venous Thromboembolism in the Emergency Department. American Society of Hematology December 2019 (poster presentation). Orlando, Florida.

### **PUBLICATIONS**

1. Deitelzweig SB, Medical management of venous thromboembolic disease. *The Ochsner Journal*. 2000; 2 (2):92-101.
2. Deitelzweig SB, Management and prevention of venous thromboembolism including surgery and the pregnant state. *The Ochsner Journal*. 2002; 4 (1) 23-9.
3. Deitelzweig SB, Vanscoy GJ, Niccolai CS, et al. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients. *Ann Pharmacother*. 2003; 37 (3) 402-11
4. Deitelzweig, SB, Jaff MR, Medical management of venous thromboembolic disease. *Tech Vasc Interv Radiol*. 2004; 7 (2) 63-7.
5. Deitelzweig SB, McKean, SC, Amin, AN, et al. Prevention of venous thromboembolism in the orthopedic surgery patient. *Cleve Clin J Med*. 2008; 75 Suppl (3) S27-36.
6. Deitelzweig SB, Hoeksra JW. Peripheral arterial disease and the hospitalist: the rationale for early detection and optimal therapy. *J Hosp Med*. 2008; 3 Suppl (2) S4-8.
7. Deitelzweig SB, Becker R, Lin J, et al. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. *Thromb Haemost*. 2008; 100 (5) 810-20.
8. Del Cid MR, Anand, RG, Sossaman GN, et al. Cardiac sarcoidosis: a case report and review of the literature. *J La State Med Soc*. 2008; 160 (3) 155-9.
9. Deitelzweig SB, Sasahara A, Michota F, McKean SC, Jacobson A. Guidelines-based use of thromboprophylaxis. *J Hosp Med*. 2009 Oct 14;4(S8):S8-S15.
10. McKean SC, Deitelzweig SB, Sasahara A, Michota F, Jacobson A. Assessing the risk of venous thromboembolism and identifying barriers to thromboprophylaxis in the hospitalized patient. *J Hosp Med*. 2009 Oct;4(8 Suppl):S1-S7.
11. Michota F, Connor PJ, McKean SC, Deitelzweig SB, Sasahara A, Jacobson A. Improving thromboprophylaxis: performance measures and practical strategies. *J Hosp Med*. 2009 Oct;4(8 Suppl):S24-S30.
12. Sasahara A, Michota F, McKean SC, Deitelzweig SB, Jacobson A. Optimizing management of venous thromboembolism: diagnosis, treatment, and secondary prevention. *J Hosp Med*. 2009 Oct;4(8 Suppl):S16-S23.
13. Amin AN, Deitelzweig SB. Optimizing the prevention of venous thromboembolism: recent



- quality initiatives and strategies to drive improvement. *Jt Comm J Qual Patient Saf.* 2009 Nov;35(11):558-564.
14. Zarowitz BJ, Tangalos E, Lefkovitz A, Bussey H, Deitelzweig S, Nutescu E, O'Shea T, Resnick B, Wheeler A. Thrombotic risk and immobility in residents of long-term care facilities. *J Am Med Dir Assoc.* 2010 Mar;11(3):211-221.
  15. Deitelzweig SB, Lin J, Hussein M, Battleman D. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis? *J Thromb Thrombolysis.* 2010 Jul;30(1):55-66. Epub 2009 Oct 1.
  16. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD (Deitelzweig S, collaborator); EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Ann Intern Med.* 2010 Jul 6;153(1):8-18.
  17. Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. *Adv Ther.* 2010 Sep;27(9):623-633.
  18. Deitelzweig SB, Ogbonnaya A, Berenson K, Lamerato LE, Costas JP, Makenbaeva D, Corbelli J. Prevalence of stroke/transient ischemic attack among patients with acute coronary syndromes in a real-world setting. *Hosp Pract (Minneap).* 2010 Nov;38(4):7-17.
  19. Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections. *Am J Hematol.* 2011 Feb;86(2):217-220.
  20. Deitelzweig SB, Lin J, Johnson BH, Schulman KL. Venous thromboembolism in the US: does race matter? *J Thromb Thrombolysis.* 2011 Feb;31(2):133-138.
  21. Deitelzweig SB, Lin J, Lin G. Preventing venous thromboembolism following orthopedic surgery in the United States: impact of special populations on clinical outcomes. *Clin Appl Thromb Hemost.* 2011 Nov;17(6):640-650. Epub 2011 May 17.
  22. Deitelzweig SB, McCormick L. Hyponatremia in hospitalized patients: the potential role of tolvaptan. *Hosp Pract (Minneap).* 2011 Aug;39(3):87-98.
  23. Bonafede M, Jing Y, Gdovin Bergeson J, Liffmann D, Makenbaeva D, Graham J, Deitelzweig SB. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome. *Hosp Pract (Minneap).* 2011 Aug;39(3):16-22.
  24. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. *J Med Econ.* 2012;15(4):776-785. Epub 2012 Apr 13.
  25. Deitelzweig S. Preventing venous thromboembolic events after total hip arthroplasty: new developments in clinical practice. *Hosp Pract (Minneap).* 2012 Apr;40(2):79-87.
  26. Deitelzweig S, Amin A, Lin J, Christian R, Baumer D, Lowe T. Impact of hyponatremia on health care resource utilization in decompensated cirrhosis patients. *Value Health.* 2012 Jun; 15(4):A176
  27. Deitelzweig S, Dressler DD, Harte B. Update in hospital medicine: evidence published in 2011. *Ann Intern Med.* 2012 Jun 19;156(12):875-879.
  28. Rosenman MB, Baker L, Jing Y, Makenbaeva D, Meissner B, Simon TA, Wiederkehr D, Deitelzweig S. Why is warfarin underused for stroke prevention in atrial fibrillation? A

- detailed review of electronic medical records. *Curr Med Res Opin.* 2012 Sep;28(9):1407-1414. Epub 2012 Jul 26.
29. Deitelzweig SB. Transitions of care in anticoagulation management for patients with atrial fibrillation. *Hosp Pract (Minneap).* 2012 Oct;40(4):20-27.
  30. Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Belk K, Baumer D, Lowe TJ. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. *J Hosp Med.* 2012 Oct;7(8):634-639. Epub 2012 Sep 7.
  31. Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ. Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis. *Adv Ther.* 2013 Jan;30(1):71-80. Epub 2012 Dec 21.
  32. Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Lowe TJ. Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US. *J Med Econ.* 2013;16(3):415-420. Epub 2013 Jan 23.
  33. Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ. Health care utilization, costs, and readmission rates associated with hyponatremia. *Hosp Pract (Minneap).* 2013 Feb;41(1):89-95.
  34. Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, Graham J. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. *Clin Ther.* 2013 Aug;35(8):1201-1210. Epub 2013 Jul 16.
  35. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients  $\geq 75$  and  $< 75$  years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. *J Med Econ.* 2013 Sep;16(9):1163-1168. Epub 2013 Aug 8.
  36. Deitelzweig S. Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. *Ochsner J.* 2013 Fall;13(3):419-427. Feb;9(2):123-128.
  37. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on AVERROES Trial. *Clin Appl Thromb Hemost.* 2013 Oct 9. [Epub ahead of print] 2013 24108232
  38. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients  $\geq 75$  and  $< 75$  years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. *J Med Econ.* 2013 Sep;16(9):1163-1168. Epub 2013 Aug 8. 2013 23869941
  39. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks. *Cardiol Ther.* 2013 Dec;2(2):165-170. Epub 2013 Aug 17. 2013 25135394
  40. Deitelzweig S. Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. *Ochsner J.* 2013 Fall;13(3):419-427. 2013 24052775
  41. Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, Graham J. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. *Clin Ther.* 2013 Aug;35(8):1201-1210. Epub 2013 Jul 16.

- 2013 23867114
42. Deitelzweig SB, Pinsky B, Buysman E, Lacey M, Makenbaeva D, Wiederkehr D, Graham J. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. *Clin Ther*. 2013 Oct;35(10):1536-1545.e1. Epub 2013 Sep 26. 2013 24075151
  43. Fares H, Heist K, Lavie CJ, Kumbala D, Ventura H, Meadows R, Carter W, Deitelzweig S, Ray IB. Fragmented QRS complexes-a novel but underutilized electrocardiographic marker of heart disease. *Crit Pathw Cardiol*. 2013 Dec;12(4):181-183. 2013 24240545
  44. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. *J Thrombolysis*. 2014 Aug;38(2):150-159. Epub 2014 Jan 30. 2014 24477787
  45. Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. Hospitalistperspective on the treatment of skin and soft tissue infections. *Mayo Clin Proc*. 2014 Jun 25. [Epub ahead of print]. 2014 24974260
  46. Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. The hospitalist perspective on treatment of community-acquired bacterial pneumonia. *Postgrad Med*. 2014 Mar;126(2):18-29. 2014 24685965
  47. Cawley P, Deitelzweig S, Flores L, Miller JA, Nelson J, Rissmiller S, Wellikson L, Whitcomb WF. The key principles and characteristics of an effective hospital medicine group: An assessment guide for hospitals and hospitalists. *J Hosp Med*. 2014
  48. Amin A, Deitelzweig S. A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. *Thromb J*. 2015 Aug 21;13:29. eCollection 2015.
  49. Deitelzweig S, Amin A. Target-specific oral anticoagulants and the hospitalist. *Hosp Pract (1995)*. 2015 Feb;43(1):1-12. Epub 2015 Jan 6.
  50. McHorney CA, Crivera C, Laliberté F, Nelson WW, Germain G, Bookhart B, Martin S, Schein J, Lefebvre P, Deitelzweig S. Adherence to non-VKA oral anticoagulant medications based on the Pharmacy Quality Alliance measure. *Curr Med Res Opin*. 2015 Sep 22:1-16.
  51. Deitelzweig S, Bruno A, Trocio J, Tate N, Gupta K, Lin J, Lingohr-Smith M. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. *Curr Med Res Opin*. 2016;32:573-82.
  52. Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Singh P, Lin J. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. *Curr Med Res Opin*. 2016;32:87-94.
  53. Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. *Microb Drug Resist*. 2016 Jul;22(5):412-431. Epub 2016 Feb 11.
  54. Deitelzweig S, Laliberté F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P. Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight

- heparin and warfarin in the outpatient setting. *Clin Ther.* 2016 Aug;38(8):1803-1816.e3. Epub 2016 Aug 2.
55. Margolis JM, Deitelzweig S, Kline J, Tran O, Smith DM, Bookhart B, Crivera C, Schein J. Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions. *J Am Heart Assoc.* 2016 Oct 6;5(10).
  56. Margolis JM, Deitelzweig S, Kline J, Tran O, Smith DM, Crivera C, Bookhart B, Schein J. Pulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarin. *Clin Ther.* 2016 Nov;38(11):2496-2503. Epub 2016 Oct 15.
  57. Deitelzweig SB, Evans M, Trocio J, Gupta K, Lingohr-Smith M, Menges B, Lin J. Impact of warfarin persistence on health-care utilization and costs among patients with atrial fibrillation managed in anticoagulation clinics in the United States. *Clin Appl Thromb Hemost.* 2017 Jan 1. [Epub ahead of print].
  58. Li, Deitelzweig, Keshishian, Hamilton, Horblyuk, Gupta, Luo, Mardekian, Friend, Nadkarni, Pan, and Lip, Effectiveness and Safety of Apixaban versus Warfarin in Non-Valvular Atrial Fibrillation Patients in “Real-World” Clinical Practice: A Propensity Matched Analysis of 76,940 Patients. *Thrombosis and Hemostasis* 2017 Feb 1.[Epub ahead of print]
  59. Deitelzweig S, Farmer C, Luo X, Vo L, Li X, Hamilton M, Horblyuk R, Ashaye A (2017). “Risk of Major Bleeding in Patients with Non-Valvular Atrial Fibrillation Treated with Oral Anticoagulants: a Systematic Review of Real-World Observational Studies,” *Current Medical Research and Opinion*, 33(9):1583-1594.
  60. Deitelzweig S, Farmer C, Luo X, Li X, Vo L, Mardekian J, Fahrbach K, Ashaye A (2017). “Comparison of Major Bleeding Risk in Patients with Non-Valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants in the Real-World Setting: a Network Meta-Analysis,” *Current Medical Research and Opinion*, <https://doi.org/10.1080/03007995.2017.1411793>.
  61. Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Hlavacek P. All-cause, stroke/systemic embolism-, and major bleeding-related health-care costs among elderly patients with nonvalvular atrial fibrillation treated with oral anticoagulants. *Clin Appl Thromb Hemost.* 2018 May;24(4):602-611. Epub 2018 Jan 24.
  62. Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, Gupta A, Pan X, Mardekian J, Lingohr-Smith M, Menges B, Marshall A, Nadkarni A. Hospital resource utilization and costs associated with warfarin versus apixaban treatment among patients hospitalized for venous thromboembolism in the United States. *Clin Appl Thromb Hemost.* 2018 Nov 15:1076029618800806. [Epub ahead of print]. PMID 30433823
  63. Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Hlavacek P, Lingohr-Smith M, Menges B, Lin J. All-cause, stroke/systemic embolism-, and major bleeding-related health-care costs among elderly patients with nonvalvular atrial fibrillation treated with oral anticoagulants. *Clin Appl Thromb Hemost.* 2018 May;24(4):602-611. Epub 2018 Jan 24. PMID 29363999
  64. Guy H, Laskier V, Fisher M, Neuman WR, Bucior I, Deitelzweig S, Cohen AT. Cost-effectiveness of betrixaban compared with enoxaparin for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United States. *Pharmacoeconomics.* 2018 Dec 21. [Epub ahead of print]. PMID 30578462

65. Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach. *PLoS One*. 2018 Jan 26;13(1):e0191722. eCollection 2018. PMID29373602
66. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. *Stroke*. 2018 Dec;49(12):2933-2944. PMID 30571400
67. Amin A, Deitelzweig S, Bucior I, Lin J, Lingohr-Smith M, Menges B, Neuman WR. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US. *J Med Econ*. 2019 Nov;22(11):1119-1125. 31084383 2019
68. Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. *J Am Geriatr Soc*. 2019 Aug;67(8):1662-1671. Epub 2019 May 21.31112292 2019
69. Deitelzweig S, Lip GYH. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. *Expert Rev Pharmacoecon Outcomes Res*. 2019 Jun;19(3):243-244. Epub 2019 Mar 18. 30870051 2019
70. Guy H, Laskier V, Fisher M, Bucior I, Deitelzweig S, Cohen AT. Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. *Expert Rev Pharmacoecon Outcomes Res*. 2019 Jun 19:1-9. [Epub ahead of print]. 31215264 2019
71. Pollack CV, Amin A, Wang T, Deitelzweig S, Cohen M, Slattery D, Fanikos J, DiLascia C, Tuder R, Kaatz S. Contemporary NSTEMI management: the role of the hospitalist. *Hosp Pract (1995)*. 2019 Dec 9. [Epub ahead of print]. 31815570 2019
72. Dager WE, Ansell J, Barnes GD, Burnett A, Deitelzweig S, Minichiello T, Triller D, Kaatz S. "Reduce the likelihood of patient harm associated with the use of anticoagulant therapy": commentary from the anticoagulation forum on the updated Joint Commission NPSG.03.05.01 Elements of Performance. *Jt Comm J Qual Patient Saf*. 2020 Jan 10. pii: S1553-7250(19)30487-8. [Epub ahead of print]. 320055122020
73. Deitelzweig S, Hlavacek P, Mardekian J, Rosenblatt L, Russ C, Tuell K, Lingohr-Smith M, Lin J, Guo JD. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department. *Hosp Pract (1995)*. 2020 Feb 6:1-8. [Epub ahead of print]. 31976776 2020
74. Geoffrey D. Barnes, Steven B. Deitelzweig. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. *Journal of Thrombosis and Thrombolysis* <https://doi.org/10.1007/s11239-020-02138-z>. 2020.

### PRESENTATIONS

1. Dementia. Winthrop Home Care Services, Minneola, N.Y. 1988.
2. Signs, Symptoms and Diagnosis of Osteoarthritis and Rheumatoid Arthritis. Herricks Senior Citizen's Center, Herricks, NY. 1988.
3. Cholesterol: Heath and Diet. The Franklin Square Senior Citizen's Center, Franklin Square, NY. 1988.
4. Hypertension; Screening for Lung Cancer. House Staff Conferences, New York. 1990.
5. Clinical Pathology Conference - Abnormal Liver Tests. Medicine Grand Rounds, Alton Ochsner Medical Foundation, New Orleans, LA. 1992.
6. MKSAP - Hepatology Review for Ochsner Medical Foundation, New Orleans, LA. 1995, 1996, 1997, 1998, 1999, 2000.
7. Thrombolytics: A Primary Care Prospective. Emory University School of Medicine, Atlanta, GA. November 1997.
8. Hospice in Long Term Care Facilities. Jefferson Healthcare Nursing Home, New Orleans, LA. July 1998.
9. Deep Vein Thrombosis. Medicine Grand Rounds, Forrest General Hospital, Hattiesburg, MS. August 1998.
10. Community-Acquired Pneumonia. Ochsner Foundation Hospital, New Orleans, LA. September 1998.
11. Deep Vein Thrombosis and Pulmonary Embolism. Medicine Grand Rounds, Alton Ochsner Medical Foundation, New Orleans, LA. November 1998.
12. Coordination of Outpatient Treatment of Deep Vein Thrombosis. Grand Rounds, Wilson Jones Hospital, Sherman, Texas. January 1999.
13. New Approaches to the Management of Venous Thromboembolic Disease. Medicine Grand Rounds, Texas Tech University, Lubbock, Texas. January 1999.
14. Coordination of Outpatient Treatment of Venous Thromboembolic Disease. Medicine Grand Rounds, Norman Regional, Norman, Oklahoma. January 1999.
15. Community-Acquired Pneumonia. East Jefferson General Hospital, New Orleans, LA. February 1999.

**CURRICULUM VITAE**

**STEVEN B. DEITELZWEIG, M.D.**

**PAGE 23**

16. DVT and PE -- Review of Catheter-Directed Thrombolytics and Low-Molecular-Weight Heparin, Chateau Elan, Atlanta, GA. February 1999.
17. New Approaches to the Management of Venous Thromboembolic Disease. Medicine Grand Rounds, Texas Tech University, Amarillo, Texas. February 1999.
18. New Approaches to the Management of Venous Thromboembolic Disease. Reunion Arena, Dallas, Texas. February 1999.
19. Prophylaxis of Venous Thromboembolic Disease. East Jefferson General Hospital Family Practice Program Grand Rounds, New Orleans, LA. April 1999.
20. DVT and Pulmonary Embolus: A Case Manager's and Medical Director's Perspective. April 1999.
21. How To Develop a Hospitalist Program. Ocean Springs, MS. April 1999.
22. Ochsner Pneumonia Pathway: Clinical implications. Hattiesburg, MS. April 1999.
23. DVT and Pulmonary Embolus: New Frontiers. Medicine Grand Round, Caraway Methodist Hospital, Birmingham, AL. June 1999.
24. DVT and Pulmonary Embolus: New Frontiers. Family Practice Board Review course. University of Arkansas, Fort Smith, Arkansas. June 1999.
25. Low-Molecular Heparin in Managed Care, NYL Care. Dallas, TX. August 1999.
26. Outpatient Treatment Protocols for venous thromboembolic Disease. Aetna, Houston, TX. August 1999.
27. How to Interface with the Hospitalist. POA Meeting for Bristol Myers Squibb. August 1999.
28. Hospice in the Long-Term Care Setting. Administration in Louisiana Nursing Homes. September 1999.
29. Advances in the Management of Pain and Arthritis Condition. Oklahoma City, OK, and Baton Rouge, LA, Orthopedic Journal Club. October 1999.
30. Community-Acquired Pneumonia - Ochsner; Pathway and Clinical Results. Medical Grand Round. November 1999.
31. Cox-2 Inhibitors. A Hospitalist Perspective with Gastrointestinal Protective Effects. Alexandria, LA. November 1999.
32. Aventis National Area Education programs. Evidence-Based Approach to Use of Low Molecular Weight Heparins. January 2000 - June 2000.
33. Influenza and Pneumonia. Where have we been and where are we going. Family Practice

- Journal Club. Mandeville, LA. January 2000.
34. Update in Pain Management: A Hospitalist's Perspective. Alexandria, LA. April 2000.
  35. How to Develop and Implement an Outpatient DVT Protocol. Medical Grand Rounds. Naples Community Hospital. April 2000.
  36. Reassessing Risk of the Medically Ill Patient: A Targeted Approach to Antithrombotic Therapy. Section leader to a closed consultants' meeting for Rhone-Poulenc Rorer. San Antonio, TX. May 2000.
  37. The Use of LMWH's in the 2000's. Martin Memorial Medical Center. Stuart, FL. May 2000.
  38. Hospice and Hospital Medicine by the Hospitalist. Trinity Hospice Medical Directors' Retreat. Bradford, PA. June 2000.
  39. The Use of LMWH's in the 2000's. Texas Heart Institute. Houston, TX. June 2000.
  40. Community-Acquired Pneumonia: Care across the Continuum. Memorial Medical Center Noon Conference. June 2000.
  41. Current Approaches to the Clinical Uses of LMWH. University of South Florida Family Practice Residency. July 2000.
  42. Clinical Uses of the Low Molecular Weight Heparins. NMA. Lafayette, Louisiana. August 2000.
  43. Prophylaxis of the Medically Ill and Acute Coronary Syndromes. Tampa Regional Medical Center. August 2000.
  44. Implementation of Protocol Development by a Hospitalist. Round-table discussion. Tampa Hospitalists. August 2000.
  45. CAP Pathway. Clinical Outcomes by risk stratification. Metairie, Louisiana. August 2000.
  46. State of the Art Symposium on Low Molecular Weight Heparin and Pharmacoeconomics. Primed Northeast. Boston, Massachusetts. September 2000.
  47. Differentiation of LMWH's. Medicine Grand Round at Forrest General Hospital, Hattiesburg, Mississippi. August 2000.
  48. Pain Management and JCAHO. Lafayette, Louisiana. September 2000.
  49. Current and New Uses for LMWH: Bridging for Arterial and Venous Disease, Pregnancy, ACS, VTE. West Florida Regional Medical Center. October 2000.



50. LMWH in the Managed Care Arena. TennCare. Nashville, Tennessee. October 2000.
51. Clinical Uses of LMWH: Arterial or Venous Disease. Northwest Regional Medical Center Grand Round. October 2000.
52. Inpatient and Outpatient Approaches to Community-Acquired Pneumonia. Hattiesburg, Mississippi. November 2000.
53. Use of LMWH's. Dinner Symposium. December 2000.
54. State of the Art Approaches to Venous Thromboembolic Disease from Heparin to Thrombolytics. Pearl Harbor Academy. Honolulu, Hawaii. December 2000.
55. How to Design an Outpatient VTE Protocol. Summit Hospital Grand Round. McComb, Mississippi. January 2001.
56. JCAHO/EPEC Manual Regarding Pain Management. Regional Medical Directors' Retreat. Biloxi, Mississippi. January 2001.
57. New Approaches to the Management of Venous Thromboembolic Disease. Halifax Hospital Grand Rounds. Daytona Beach, Florida. February 2001.
58. Clinical Uses of Heparins. University of South Carolina. February 2001.
59. Acute Coronary Syndrome, VTE, and Prophylaxis of the Medically Ill. Athens Regional Medical Center. Athens, Georgia. March 2001.
60. Prophylaxis of the Medically Ill and Surgical Patients – Risk Stratification. Austin, Texas. April 2001.
61. Pain Management with Pre-Emptive Analgesia for the Hospitalized Patient. Lafayette, Louisiana. April 2001.
62. Venous Thromboembolic Disease Prophylaxis for the Obese: An Evidence-Based Approach. Fobi Clinic, Los Angeles, California. May 2001.
63. Clinical Uses of the Low Molecular Weight Heparin. White Memorial Medical Center. Los Angeles, California. May 2001.
64. Tifacogin and Tissue Factor Pathway Inhibition: Advisor and Discussant. Chicago, Illinois. May 2001.
65. Diagnosis and Treatment of Venous Thromboembolic Disease. Closed Consultant National Meeting. Aventis Pharmaceuticals. Vancouver, Canada. May 2001.
66. Outpatient VTE Treatment Workshop. Closed Consultant National Meeting. Aventis Pharmaceuticals. Carlsbad, California. June 2001.

67. State of the Art Symposium on Low Molecular Weight Heparin and Pharmacoeconomics. Primed Mid West. Chicago, Illinois. June 2001.
68. Cardiovascular, Renal, Gastrointestinal Effect of Coxibs in the Hospitalized Patient. New Orleans, Louisiana. June 2001.
69. LMWH and Cancer. International Society for Thrombosis and Hemostasis. Paris, France. July 2001.
70. LMWH: An Update on Bridging Louisiana Education for Anticoagulation Research Network. New Orleans, Louisiana. November 2001.
71. New Cardiovascular Horizons Faculty. Heparins and VTE. New Orleans, Louisiana. November 2001.
72. PAD for the PCP. New Orleans, Louisiana. December 2001.
73. New Anticoagulants: What you need to know. Halifax Hospital Grand Rounds. Daytona Beach, Florida. February 2002.
74. 5<sup>th</sup> Annual VTE Experts and INATE (Investigators Against Thromboembolism) Meeting. Participant. Barcelona, Spain. March 2002.
75. Care-Based Consultants' Meeting for Medically Ill Patients at Emory University School of Medicine. March 2002.
76. What a Hospitalist Should Know About Anticoagulation. Inpatient Physician of Forsyth Winston-Salem, North Carolina. April 2002.
77. Medical and Surgical Prophylaxis of VTE. Nashville, Tennessee. May 2002.
78. VTE Awareness Campaign. WDSU – Channel 6. New Orleans, Louisiana. June 2002.
79. VTE Treatment Area Consultant Forum. Memphis, Tennessee. June 2002.
80. VTE Awareness. Department of Medicine, Grand Rounds at Ochsner Clinic Foundation. New Orleans, Louisiana. June 2002.
81. Anticoagulation for the Orthopedist. Ochsner Clinic Foundation, Grand Rounds. New Orleans, Louisiana. June 2002.
82. Management of Acute Coronary Syndrome and Bridging Hospitalists of Broward County. Fort Lauderdale, Florida. July 2002.
83. "Bridging" the Surgical Patient. WDSU – Channel 6. New Orleans, Louisiana.

- August 2002.
84. Care-Based Consultant Meeting for the Southeastern Region on Anticoagulation Issues. Asheville, North Carolina. August 2002.
  85. Care-Based Consultant Meeting for the Northeastern Region on DVT and Pulmonary Embolism and Thrombophilia. Conducted with Dr. Sam Goldhaber as co-moderator. Boston, Massachusetts. September 2002.
  86. LMWH and Thrombolytics in VTE Management for the Cardiologist. New Cardiovascular Horizons. New Orleans, Louisiana. October 2002.
  87. Hospitalists and Heart Failures: New Algorithms for Care. Phoenix, Arizona. November 2002.
  88. How to Initiate a VTE Prevention Campaign. Inpatient Physicians of Memphis / Annual Meeting. December 2002.
  89. LMWH and Cancer. Halifax Tumor Conference. Daytona Beach, Florida. January 2003.
  90. Use of Antithrombotic agents during pregnancy. Obstetrics grand rounds. Ochsner Clinic Foundation. January 2003.
  91. VTE: State of the Art. Medical Grand Rounds at North Shore – Long Island Jewish Health System. New York, New York. April 2003.
  92. DVT-Free: One Health System's Experience. St. Thomas, Virgin Islands. April 2003.
  93. National UPA Consensus panel: Co-chair, Venous Thromboembolism. Cancun, Mexico. May 2003.
  94. Challenging Venous Thromboembolism Standards: Heparin, LMWHs, and Evolving Agents. Memphis, Tennessee. May 2003.
  95. Management of VTE. Medical Grand Round. North Shore Glencove and Forest Hills, New York, New York. June 2003.
  96. Prevention and Treatment of DVT in the Medically Ill Patient. St. Mary's Hospital. Knoxville, Tennessee. July 2003.
  97. Healthday.com Top News Story. Preventive Blood Clot Therapy Underused Review of ISTH Meeting. July 2003.
  98. 2003: VTE Update State of the Art. Carolinas Medical Center. October 2003.
  99. Optimal Management of the Hospitalized Patient. "Big Easy Fall Symposium." Conference director. New Orleans, Louisiana. October 9-11, 2003.

100. VTE for the At-Risk Rehabilitation Patient. National Meeting for the Association of Rehabilitation Nurses. New Orleans, Louisiana. October 2003.
101. VTE in the Renal Impaired and Novel Anticoagulants. UMKC / Truman Medical Center. Kansas City, Missouri. November 2003.
102. Management of VTE in special patient populations. St. Luke's Hospital. Kansas City, Missouri. November 2003.
103. Visiting Professorship at University of Kansas/Wichita. December 2003.
104. How to Develop, Implement, and Monitor a VTE Awareness Initiative. Medicine grand round. UT – Galveston. December 2003.
105. Preventing Venous Thromboembolism among Hospitalized Patients. A VHA one-hour Simulcast to 2300 hospitals featuring Ochsner Clinic Foundation administrators, pharmacists, and physicians.
106. In-Hospital Management of Heart Failure from a Hospitalist's Perspective: Regional Symposium. Orlando, Florida. January 2004.
107. Advancing into a New Era of Anticoagulant Therapy. Baton Rouge, Louisiana. January 2004.
108. The U.S. DVT Safety Zone Initiative. Curve Investigator's Meeting. Montreal, Canada. January 2004.
109. Update in CHF Management. East Tennessee Society of Hospital Medicine. Bristol, Tennessee. February 2004.
110. VTE Care Presentation and Update. VT Houston. Section of Pulmonary Medicine. February 2004.
111. Vascular Disease. NPR. March 2004.
112. Advancing Into A New Era of Anticoagulant Therapy. Knoxville, Tennessee. April 2004.
113. Challenging Venous Thromboembolism Standards: Heparin, LMWHs and Evolving Agents. UPA Scientific Panel. Sanibel, Florida. April 2004.
114. The Evolving Role of the Hospitalist in the Management of Acute Decompensated Heart Failure. Annual Meeting SHM. New Orleans, Louisiana. April 2004.
115. Visiting Professorship at Good Samaritan Hospital Department of Surgery and St. John Hospital Department of Medicine. Phoenix, Arizona. April 2004.

116. Optimizing Injectable Anticoagulant Formulary Management: LMWHs and Novel Agents. Intermountain Health Systems. Salt Lake City, Utah. May 2004.
117. How to Initiate A VTE Awareness Program. New Bern, North Carolina. July 2004.
118. ADHF Update. Hospitalist Advisory Board. Amelia Island, Florida. August 2004.
119. VTE 2005 – Medicine Grand Rounds. Kessler Air Force Base. Biloxi, Mississippi. August 2004.
120. Coumadin in the Twenty-First Century. Augusta, Georgia. October 2004.
121. Course Director and Presenter at the Second Annual Optimal Management of the Hospitalized Patient. New Orleans, Louisiana. October 2004.
122. Coumadin in the Twenty-First Century. Brooklyn VA. Brooklyn, New York. November 2004.
123. Consensus on Contemporary Issues With Unfractionated Heparin: Challenges in Variation and Responsiveness ASHP. Orlando, Florida. December 2004.
124. VTE: Get With the Guidelines. AHEC Grand Rounds. Charlotte, North Carolina. March 2005.
125. Optimizing Observation Patient Management by the World Research Group. Orlando, Florida and Las Vegas, Nevada. March 2005 and April 2005.
126. Hospital Medicine Update. At SHM. Chicago, Illinois. April 2005.
127. How to Design, Implement, and Maintain the DVT Safety Zone. VTMB. Galveston, Texas. May 2005.
128. Vascular Diseases and Core Measures. Third Annual Stroke Conference at Ochsner Clinic Foundation. New Orleans, Louisiana. May 2005.
129. Management of decompensated heart failure from a hospitalist perspective. Phoebe Putney Memorial Family Medicine Residency – Affiliate of MCG. Albany, Georgia. May 2005.
130. Covering the Hospital Patient: Planning Hospitalist and House Staff Coverage. Fiftieth Annual Six-Clinic Meeting. Boston, Massachusetts. June 2005.
131. Oral Anticoagulants in the Twenty-First Century. UT – Knoxville. Knoxville, Tennessee. June 2005.
132. VTE and the medically ill patient. Medical Grand Rounds. Huntington Hospital. NSUH/LIJ health system. September 2005.

133. New anticoagulants. What does the future hold. Appleton Medical Center. Greenbay, Wisconsin. September, 2005.
134. Medical Management during Hurricane Katrina. Implications to Hospitalists. 6<sup>th</sup> Annual Hospital Medicine Update. Atlanta, Georgia. November 10-12, 2005.
135. Co-chair with Dr. Mark Williams 6<sup>th</sup> Annual Southern Hospital Medicine Update. Atlanta, November 10-12, 2005.
136. The Katrina Clot and hospital medicine. Department academic presentation. Medical College of Virginia. November 2005.
137. Creating a Culture of Safety. Where there is alliance in NQF, JCAHO, and AHRQ University of Miami. Miami, Florida. January 2006.
138. The development of a VTE awareness initiative: Lessons Learned. Emory Hospital Medicine Department. Atlanta, Georgia. February 2006.
139. Get with the Guidelines: 2006 ACCP consensus update. Penbrook Memorial Hospital. Colorado Springs, Colorado. March 2006.
140. DVT Awareness Month and Hospital Medicine. HCA Lakeside Hospital. Mandeville, LA. March 2006.
141. Moderator for Hospital Medicine and Perioperative initiatives. Annual Meeting for the Society of Hospital Medicine. Washington, DC May 2006.
142. Moderator for Sanofi-Aventis National Advisory Board for Congestive Heart Failure and Prevention of VTE. Santa Fe, New Mexico. May 2006.
143. Thrombosis in 2007. AMCP. Chicago, Illinois. September 2006
144. Enoxaparin for DVT Prophylaxis in the Medically Ill Patient. Summit Medical Center. Hermitage, Tennessee. October 2006.
145. What It Takes To Improve Clinical Outcomes. Faculty for Hospital and Physician Relations: An Executive Summit. Co-presented with Sue Bond of HealthGrades. Scottsdale, Arizona. October 2006.
146. Core Measures: What a Hospitalist Needs To Know. Kessler AFB. Biloxi, Mississippi. October 2006.
147. Course director and presenter for the 7th Annual Hospital Medicine Update co-sponsored with Emory. New Orleans, LA. November 2006.
148. Quality Measures for 2007 in Vascular Diseases. Grand Rounds for Dept of Medicine at Jewish General Hospital. Montreal, Canada. January 2007.

149. Heparin Induced Thrombocytopenia. San Antonio, Texas. January 2007.
150. Quality Measures: What happens if you don't make the leap?. Miami, Florida. February 2007.
151. VTE in the Rehab patient. Grand Rounds at the Tampa VA. March 2007.
152. Core measures: What is new on the horizon? Medicine Grand Rounds. West Virginia University. March 2007.
153. Anticoagulation in the long term care patient. Chairman and moderator. New York City, New York. April 2007.
154. VTE and Quality: Satellite symposium at SHM national meeting. Dallas, Texas. May 2007.
155. Peripheral Artery Disease and Antiplatelets for the Hospitalist. Satellite symposium at the SHM national meeting. Dallas, Texas. May 2007.
156. Core Measures: What happens if you don't make the Leap? Grand Rounds. Castle Medical Center, Hilo Medical Center. Oahu and Hilo, Hawaii. July 2007.
157. Conference co-director and presenter at the ninth annual southern hospital medicine update Ochsner/Emory. New Orleans, LA. October 2007.
158. Leadership directives and core measures international investigations against thromboembolism. Lisbon, Portugal. October 2007.
159. Improving Patient Care through GME: Outcome Measures. The AIAMC National Initiative. Washington, DC. November 2007.
160. Cleveland Clinic VTE Symposium. Orthopedic initiatives. Miami, FL. December 2007.
161. Patient Satisfaction; The physician: role Ground rounds: Ochsner Medical Center New Orleans, LA. January 2008.
162. DVT and PE Prophylaxis in Patients with Cancer. Valley Presbyterian Hospital Medical Staff. Van Nuys, California. February 2008.
163. Perioperative Management:Anticoagulation Society of Hospital Medicine Annual Meeting San Diego, CA April 2008.
164. SCIP and VTE management in the Vascular Surgery Patient. 9<sup>th</sup> Annual Vascular Symposium. Honolulu, Hawaii. April 2008.
165. Hospital Pharmacoeconomics of DVT Prophylaxis and Treatment. Rancho Mirage Medical Center Grand Rounds. Rancho Mirage, California. May 2008.

166. New approaches to managing VTE and quality measures. Medical Grand Rounds. Keesler Air Force Base. Biloxi, Mississippi. May 2008.
167. Patient Satisfaction. Gulf Coast States Chapter of the Society of Hospital Medicine. Conference Co-Director. Point Clear, Alabama. July 2008.
168. Quality in our Health System. Hospital Medicine Monthly Meeting Hackensack, NJ September 2008
169. Are Surgical Patients at Risk of Venous Thromboembolism Currently Meeting the Surgical Care Improvement Performance Target Goal for Appropriate and Timely Prophylaxis? ACCP Annual Meeting Philadelphia, Pennsylvania. October 2008
170. Are we Lean Enough in Healthcare. Chief Medical Officers Forum. Health Management Academy. Palm Beach, Florida. April 2009.
171. Venous Thromboembolic Disease Treatment update. Focus on the 8<sup>th</sup> ACCP guidelines. Society of Hospital Medicine Annual Meeting. Chicago, Illinois. May 2009.
172. A case-based review of the National Quality Forum / Joint Commission Resources Consensus Standards for the Prevention and Care of Venous Thromboembolism. Wisconsin. 2009.
173. Are we Lean Enough in Health Care? System ED meeting. Ochsner Health System. New Orleans, LA. June 2009.
174. Prevalence of Venous Thromboembolism in the USA: Now and In the Future. International Society of Thrombosis and Hemostasis. Boston, Mass. July, 2009.
175. Lean Performance Improvement and Re-admission Rates. Gulf States Hospitalist Society. Co-Director. Point Clear, Alabama. July 2009.
176. VTE management in the Acutely ILL Medical Patient Across the Health Care Continuum. Western Pennsylvania Hospital. Pittsburgh, PA. September 2009.
177. Intervention for Improving Care in the Hospital. Grand Rounds at Brockton Hospital. Boston, Mass. September 2009.
178. Clinical Thrombosis cases and update from the literature. 10th Annual Southern Hospital Medicine meeting. New Orleans, LA. October 2009.
179. Patient Services Experience at Ochsner Health System. GE learning, innovation, and growth program. Health Management Academy. Crotonville, New York. February 2010.
180. VTE update and care transitions. University of Miami Grand Rounds. Miami, Florida March 2010.
181. Managing the Care Transition: The Essentials of Effective Discharge Planning. Florida SHM



- Chapter Meeting. Miami, Florida. March 2010.
182. Current trends and future projections on the prevalence of venous thromboembolism in the USA. CDC National conference on Blood Disorders in Public Health. Atlanta, Georgia. March 2010.
  183. The Hospitalist and the Patient Care Team: Working Together Toward Quality Outcomes. National Teleconference with Dr. Mark McClellan. Bridgewater, New Jersey. March 2010.
  184. Teamwork and Group Effectiveness: Practice Management Workshop. Annual Society of Hospital Medicine Meeting 2010. Washington, DC. April 2010.
  185. Guidelines in the Hospital to Meet Joint Commission Measures and Achieve National Patient Safety Goals. Annual Society of Hospital Medicine Meeting 2010. Washington, DC. April 2010.
  186. Teamwork and Group Effectiveness. Annual Meeting of the Society of General Internal Medicine. Minneapolis, Minnesota. May 2010.
  187. The Importance of Ensuring Appropriate DVT Prophylaxis Throughout the Continuum of Care. Medical Grand Rounds. Danbury Hospital and White Plains Hospital. Danbury, CT and White Plains, NY. May 2010.
  188. Deitelzweig S., Lin J., et al. Impact of Special Populations on Thromboprophylaxis and Clinical Outcomes of Patients undergoing Knee Replacement Surgery in the U.S. Abstract: Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference. Washington, D.C. May 2010
  188. Trends in the Prevalence of Venous Thromboembolism in the United States. 21<sup>st</sup> International Thrombosis Congress. Milan, Italy July 2010.
  189. Hyponatremia and its implications in the inpatient setting. Invited speaker to the New York SHM-ACP chapter meeting. New York, NY. September 2010
  190. Teamwork and Communication. Southern Hospital Medicine Conference. Atlanta, Georgia. October 2010.
  191. Dilemmas in VTE management and new anticoagulants. Southern Hospital Medicine Conference. Atlanta, Georgia. October 2010.
  192. Hyponatremia and quality metrics. SHM Houston chapter meeting. Houston, Texas. October 2010.
  193. Impact of CMS VTE Hospital Acquired Conditions (HAC) Policy on Hospital Cost and Revenue Associated with Major Surgical Hip and Knee Procedures. American Society of Hematology. Orlando, Florida. December 2010.
  194. The CMS policy on venous thromboembolism as a hospital acquired condition: projected r

- revenue and cost impact of potential expansion to include medical and surgical patients. SH. Orlando, Florida. December 2010.
195. New anticoagulants in the management of atrial fibrillation. LSU neurology and family practice residency program. March 2011.
  196. Patient satisfaction and Contemporary management of acute decompensated heart failure. Invited speaker for the inaugural Hospital Medicine pre-course at the Annual ACP meeting. San Diego, California April 2011.
  197. Hyponatremia for the hospitalist. Gulf States Hospitalist Society. Point Clear, Alabama. July 2011.
  198. NOACs and their implications in the future. Southern Hospital Medicine Conference New Orleans, LA Oct 2011.
  199. Non-monetary compensation for hospitalists. Annual Meeting Society of Hospital Medicine. San Diego, California. April 2012.
  200. Update in Hospital Medicine. American College of Physicians. New Orleans, LA. April 2012.
  201. Transitions of Care. Gulf States Hospitalist Society. Point Clear, Alabama. July 2012.
  202. Venous Thromboembolic disease update from the 9<sup>th</sup> American College of Chest Physicians. Atlanta, Georgia. October 2012.
  203. Improving Patient Satisfaction - Two Success Stories. Society of Hospital Medicine. Washington, D.C. May 2013.
  204. Patient Experience: Practical tips to improve care tomorrow. Society of Cardiovascular Patient Care Annual Symposium. Orlando, Florida. September 2013
  205. NOACs: How best to incorporate into your practice. Annual Southern Hospital Medicine conference. New Orleans, Louisiana. November 2013
  206. Tactics to improve the care of Patients with Atrial Fibrillation and Deep Vein Thrombosis. Emergencies in Medicine. Maui, Hawaii. December 2013.
  207. Leading Insights in Anticoagulation: Innovations in Practice. Cleveland Clinic and University of Miami Peri-operative Summit. Phoenix, Arizona. February 2014.
  208. The Key Principles and Characteristics of an Effective Hospital Medicine Group: An Assessment Guide for Hospitals and Hospitalists. Society of Hospital Medicine Annual Meeting. Practice Management Session. Las Vegas, Nevada. March 2014.
  209. Hospitalist and Emergency Medicine Collaborative. EDPMA. New Orleans, Louisiana. May

- 2014.
210. NOACs and 9<sup>th</sup> ACCP anticoagulation update. Regional Chapter Meeting. Honolulu, Hawaii. June 2014.
  211. The Key Principles and Characteristics of an Effective Hospital Medicine Group: An Assessment Guide for Hospitals and Hospitalists. Regional Chapter Meeting. Gulf States Hospitalist Society. Point Clear, Alabama. June 2014.
  212. Key Principles and Characteristics of an Effective Hospital Medicine Group. Inaugural Mayo Clinic Hospital Medicine Grand Rounds. Rochester, Minnesota. August 2014.
  213. VTE controversies. 15<sup>th</sup> Annual Southern Hospital Medicine Conference: Collaborative Solutions Across Healthcare. Atlanta, Georgia. October 2014.
  214. Thrombosis in the 21<sup>st</sup> century. Emergencies in Medicine Symposium. Maui, Hawaii. December 2014.
  215. Hospital Medicine Alignment. Annual Society of Hospital Medicine Conference. National Harbor Washington, DC April 2015.
  216. Hot Topics in Medicine: Continuing Education Tour. I provided 6 hours of CME and CEU. Morocco, Africa. May 2015.
  217. How to Implement the Key Characteristics of an Effective HMG. Gulf States Hospitalist Society. Point Clear, Alabama. July 2015.
  218. Case Based Update on the Use of Anticoagulants. Southern Hospital Medicine Symposium. New Orleans, Louisiana. October 2015.
  219. 36<sup>th</sup> Current Concepts in Emergency Care. Electrolyte Abnormalities in Liver Failure, Heart Failure, and Renal Failure. Maui, Hawaii. December 2015.
  220. Practice Management Pre-Course. Focus on the Key Characteristics of an Effective Hospital Medicine Group. Principles on Alignment, Recruitment, Adequate Resources. Society of Hospital Medicine. San Diego, California March 2016.
  221. Case Studies in Atrial Fibrillation and Chronic Kidney Disease. Society of Hospital Medicine Annual Meeting. San Diego, California March 2016.
  222. Hot Topics in Medicine: Continuing Education Tour. I provided 6 hours of CME and CEU. Tokyo, Japan. April 2016.
  223. Medicine on the Beach. 2016 VTE ACCP Update. Singing River Conference for PCPs. Destin, Florida April 2016.
  224. ACCP Update. Gulf States Hospitalist Society. Point Clear, Alabama July 2016.

225. Real World Data NVAF advisory board chair for the American College of Cardiology. Buenos Aires, Argentina August 2016.
226. Top Practice Management Strategies for a Successful Hospital Medicine Practice. 17<sup>th</sup> Annual Southern Hospital Medicine Conference. Atlanta, Georgia October 2016.
227. Case Based VTE Management in 2016: Guidelines, Best Evidence, and Best Practice. 17<sup>th</sup> Annual Southern Hospital Medicine Conference. Atlanta, Georgia October 2016.
228. Anticoagulation for the Internist: Pragmatic Tips. Louisiana 2017 Chapter Scientific Meeting. New Orleans, Louisiana February 2017.
229. Hospital Medicine: A Day on Service. Internal Medicine Annual Meeting. American College of Physicians. San Diego, California March 2017.
230. Real World Data. Anticoagulation Forum National Conference. Los Angeles, California April 2017
230. Key Characteristics of a High Performing Hospital Medicine Group and Venous Thromboembolic Management updates. Society of Hospital Medicine Chapter Meeting. Honolulu, Hawaii April 2017.
231. Updates in VTE Management. Christus and South Central Regional Medical Center. Laurel, Mississippi and Alexandria, Louisiana May 2017.
232. Hot Topics in Anticoagulation. Gulf States Hospitalist Society. Point Clear, Alabama July 2017.
233. Comparison of Stroke and Major Bleeding Risk of Treatment with Apixaban vs. Rivaroxaban and Dabigatran Among Elderly Nonvalvular Atrial Fibrillation (NVAF) Patients in the United States. European Society of Cardiology. Barcelona, Spain. August 2017.
234. Effectiveness and Safety of 5 mg and 2.5 mg Twice-daily Apixaban Compared to Warfarin among Non-Valvular Atrial Fibrillation Patients: A Propensity Score Match Analysis. European Society of Cardiology. Barcelona, Spain. August 2017.
235. Effectiveness and Safety of Apixaban versus Warfarin among ‘High-Risk’ Subgroups of Non-Valvular Atrial Fibrillation Patients: A Propensity Score Match Analysis. European Society of Cardiology. Barcelona, Spain. August 2017.
236. Case Based Strategies for Successful Anticoagulation Management. 18<sup>th</sup> Annual Southern Hospital Medicine Conference. New Orleans, Louisiana October 2017.
237. NVAF and VTE Real World Data for DOACs - A Global Perspective. Multiple Educational Lectures in Sydney, Gold Cost, and Brisbane, Australia. November 2017.

238. 38th Current Concepts in Emergency Care. Case Based Updates in Hospital Medicine for the ED, Pulmonary Embolus: Updates from ACCP, AC Forum, and ESC, RCT and RWD: Methodology, DOAC data, and applying to clinical practice. Maui, Hawaii. December 2017.
239. Comparison of Effectiveness, Safety, and the Net Clinical Outcome Between Different Direct Oral Anticoagulants in 162,707 Non-Valvular Atrial Fibrillation Patients Treated in US Clinical Practice. American College of Cardiology. Orlando, Florida. March 2018.
240. Deep Vein Thrombosis and Pulmonary Embolus: Updates From ACCP, AC Forum & ESC. Gulf States Hospitalist Society. Point Clear, Alabama July 2018.
241. New Strategies to Prevent CV Events After Hospital Discharge. International Society of Thrombosis and Hemostasis. Dublin, Ireland. July 2018.
242. Comparisons of Clinical and Economic Outcomes between Non-VKA Oral Anticoagulants among Non-valvular Atrial Fibrillation Patients: The ARISTOPHANES Study. European Society of Cardiology annual symposium Munich, Germany. August 2018.
243. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants among Very Elderly Patients with Non-Valvular Atrial Fibrillation: An Observational Study (Oral Presentation). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
244. Non-Vitamin K Antagonist Oral Anticoagulants Associated with Lower Stroke Rates Compared to Warfarin among Very Elderly Patients with Non-valvular Atrial Fibrillation: An ARISTOPHANES Subgroup Analysis (Moderated Digital Poster). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
245. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants among Patients with Non-Valvular Atrial Fibrillation and Diabetes (Poster). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
246. Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin among Patients with Non-Valvular Atrial Fibrillation and Diabetes: ARISTOPHANES Diabetes Subgroup Analysis (Poster). American Heart Association Scientific Session. Chicago, Illinois. November 2018.
247. VTE Prevention in the Hospitalized Medically Ill Patient. A collaboration from The Anticoagulation Forum & The Society of Hospital Medicine. Society of Hospital Medicine Chapter Meeting. Los Angeles, California. November 2018.
248. VTE Prevention in the Hospitalized Medically Ill Patient. A collaboration from The Anticoagulation Forum & The Society of Hospital Medicine. Inaugural North Florida

- Society of Hospital Medicine Chapter Meeting. Gainesville, Florida. November 2018.
249. VTE Prevention in the Hospitalized Medically Ill Patient. A collaboration from The Anticoagulation Forum & The Society of Hospital Medicine. Society of Hospital Medicine Chapter Meeting. New Orleans, Louisiana. November 2018.
  250. Real World Data: The good, the bad, and the ugly. Hospital Medicine lecture series. Charlotte, North Carolina. February 2019.
  251. Red, White and Bleed: Managing Antithrombotic Therapy in Patients with Major Bleeding. Society of Hospital Medicine Annual Meeting. Washington, DC. March 2019.
  252. Answers to YOUR Common Questions on Venous Thromboembolic Disease (VTE) and Anticoagulation. Washington, DC. March 2019.
  253. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus NOAC Among Frail Patients with Non-Valvular Atrial Fibrillation: An Observational Study (Oral Presentation). American College of Cardiology annual symposium (oral moderated poster presentation). New Orleans, Louisiana. March 2019.
  254. Broward Health Cardiology Symposium. RWD and evolving science. Fort Lauderdale, FL. March 2020
  255. Thrombosis in the Hospitalized COVID Positive Patient: Practical experiences and advice from the experts. Anticoagulation Forum and Society of Hospital Medicine. April 2020
  256. Predictors of Treatment of Hospitalized Patients with Atrial Fibrillation in the US. American Heart Association. Oral Presentation. Virtual symposium. November 2020.

More than 200 additional presentations to internal medicine and family practice house staff and attendings on various internal medicine and subspecialty topics.